-
EP4267574
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4267574
| EP4267574 - 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 24.05.2024 Database last updated on 05.07.2024 | |
| Former | Request for examination was made Status updated on 29.09.2023 | ||
| Former | The international publication has been made Status updated on 02.07.2022 | ||
| Former | unknown Status updated on 31.01.2022 | Most recent event Tooltip | 29.05.2024 | New entry: Despatch of examination report + time limit | Applicant(s) | For all designated states AJAX THERAPEUTICS, INC. 275 Madison Avenue, 39th Floor New York, NY 10016 / US | [2023/44] | Inventor(s) | 01 /
MASSE, Craig E. New York, New York 10016 / US | 02 /
GREENWOOD, Jeremy R. New York, New York 10036 / US | 03 /
MONDAL, Sayan New York, New York 10036 / US | 04 /
XU, Jiayi New York, New York 10036 / US | 05 /
GHANAKOTA, Phani New York, New York 10036 / US | 06 /
MCROBB, Fiona Michelle New York, New York 10036 / US | 07 /
BOYLES, Nicholas New York, New York 10036 / US | [2023/44] | Representative(s) | J A Kemp LLP 80 Turnmill Street London EC1M 5QU / GB | [2023/44] | Application number, filing date | 21847625.7 | 22.12.2021 | [2023/44] | WO2021US64830 | Priority number, date | US202063130251P | 23.12.2020 Original published format: US 202063130251 P | US202163218097P | 02.07.2021 Original published format: US 202163218097 P | US202163277337P | 09.11.2021 Original published format: US 202163277337 P | [2023/44] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2022140527 | Date: | 30.06.2022 | Language: | EN | [2022/26] | Type: | A1 Application with search report | No.: | EP4267574 | Date: | 01.11.2023 | Language: | EN | The application published by WIPO in one of the EPO official languages on 30.06.2022 takes the place of the publication of the European patent application. | [2023/44] | Search report(s) | International search report - published on: | EP | 30.06.2022 | Classification | IPC: | C07D471/04, C07D487/04, C07D495/04, C07D513/04, A61P35/00, A61K31/437 | [2023/44] | CPC: |
C07D471/04 (EP);
C07D519/00 (US);
A61P35/00 (EP);
C07D487/04 (EP);
C07D495/04 (EP);
C07D513/04 (EP)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2023/44] | Title | German: | 6-HETEROARYLOXYBENZIMIDAZOLE UND AZABENZIMIDAZOLE ALS JAK2-INHIBITOREN | [2023/44] | English: | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | [2023/44] | French: | 6-HÉTÉROARYLOXY BENZIMIDAZOLES ET AZABENZIMIDAZOLES UTILISÉS EN TANT QU'INHIBITEURS DE JAK2 | [2023/44] | Entry into regional phase | 01.06.2023 | National basic fee paid | 01.06.2023 | Designation fee(s) paid | 01.06.2023 | Examination fee paid | Examination procedure | 01.06.2023 | Examination requested [2023/44] | 01.06.2023 | Date on which the examining division has become responsible | 30.01.2024 | Amendment by applicant (claims and/or description) | 28.05.2024 | Despatch of a communication from the examining division (Time limit: M04) | Fees paid | Renewal fee | 27.12.2023 | Renewal fee patent year 03 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A]WO2004085425 (AMGEN INC [US]) [A] 1-50* page 203; table 8; compound 229 *; | [X]CN107383014 (UNIV SOUTHERN MEDICAL) [X] 1-50 * pages 18-26; example - *; | [A]EP3279187 (SHIONOGI & CO [JP]) [A] 1-50 * compounds I-216 *; | [A]EP3450435 (SHIONOGI & CO [JP]) [A] 1-50 * examples 35-36,38-40 *; | [I]WO2020097398 (DANA FARBER CANCER INST INC [US], et al) [I] 1-50 * pages 1-2; claim 23; compounds I-24,I-25 *; | [X] - WANG YUANYUAN ET AL, "Design, synthesis, biological evaluation and molecular modeling of novel 1H-pyrazolo[3,4-d]pyrimidine derivatives as BRAFV600Eand VEGFR-2 dual inhibitors", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, ELSEVIER, AMSTERDAM, NL, (20180602), vol. 155, doi:10.1016/J.EJMECH.2018.05.054, ISSN 0223-5234, pages 210 - 228, XP085431284 [X] 1-50 * table 1 * DOI: http://dx.doi.org/10.1016/j.ejmech.2018.05.054 | by applicant | - VAINCHENKER, W.KRALOVICS, R., Blood, (20170000), vol. 129, no. 6, pages 667 - 79 | - VAINCHENKER, W. et al., FlOOOResearch, (20180000), vol. 7, page 82 | - O'SHEA, J. J. et al., Ann. Rheum. Dis., (20130400), vol. 72, pages 111 - 115 | - RODRIGUES, M. A.TORRES, T. J., Derm. Treat., (20190000), vol. 31, no. 1, pages 33 - 40 | - MEYER S.C., LEVINE, R. L., Clin. Cancer Res., (20140000), vol. 20, no. 8, pages 2051 - 9 | - WU, S. C. et al., Cancer Cell, (20150713), vol. 28, no. 1, pages 29 - 41 | - S. M. BERGE et al., J. Pharmaceutical Sciences, (19770000), vol. 66, pages 1 - 19 | - The Lancet. doi:10.1016/S0140-6736(20)30628-0 | - YUMEEN, S. et al., Blood Adv., (20200000), vol. 4, no. 10, pages 2213 - 2226 | - JUTZI, J.S. et al., HemaSphere, vol. 2, no. 3, (20180000), URL: http://dx.doi.org/10.1097/HS9.0000000000000054 | - JAFFER, T.MA, D, Transl. Cancer Res., (20160000), vol. 5, pages S616 - S628 |